[EGFR/HER1: a target life].


EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have been extensively studied for these agents, sustaining the hallmarks of the development of molecular targeting drugs.

DOI: 10.1684/bdc.2011.1385

Cite this paper

@article{Viel2012EGFRHER1AT, title={[EGFR/HER1: a target life].}, author={Erika Viel and Elsa Curtit and L. S. A. Mansi and St{\'e}phane Vignot}, journal={Bulletin du cancer}, year={2012}, volume={99 2}, pages={181-9} }